1. Home
  2. QTTB vs TLSI Comparison

QTTB vs TLSI Comparison

Compare QTTB & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Q32 Bio Inc.

QTTB

Q32 Bio Inc.

N/A

Current Price

$8.51

Market Cap

265.2M

Sector

Health Care

ML Signal

N/A

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

N/A

Current Price

$2.17

Market Cap

250.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
QTTB
TLSI
Founded
2015
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
265.2M
250.0M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
QTTB
TLSI
Price
$8.51
$2.17
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
4
Target Price
★ $39.67
$7.80
AVG Volume (30 Days)
★ 322.9K
274.6K
Earning Date
11-04-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 136.78
N/A
EPS
N/A
★ N/A
Revenue
★ $53,737,000.00
$45,151,000.00
Revenue This Year
N/A
$3.46
Revenue Next Year
N/A
$19.48
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 53.41
52 Week Low
$1.93
$2.17
52 Week High
$23.57
$7.95

Technical Indicators

Market Signals
Indicator
QTTB
TLSI
Relative Strength Index (RSI) 41.77 28.41
Support Level $8.23 $2.20
Resistance Level $9.41 $4.41
Average True Range (ATR) 0.54 0.36
MACD -0.01 -0.07
Stochastic Oscillator 20.24 5.72

Price Performance

Historical Comparison
QTTB
TLSI

About QTTB Q32 Bio Inc.

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Share on Social Networks: